280 related articles for article (PubMed ID: 19412349)
1. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia.
Reddy A; Suri S; Sargent IL; Redman CW; Muttukrishna S
PLoS One; 2009; 4(2):e4453. PubMed ID: 19412349
[TBL] [Abstract][Full Text] [Related]
2. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
Aggarwal PK; Chandel N; Jain V; Jha V
J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
[TBL] [Abstract][Full Text] [Related]
3. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro.
Xu B; Thornton C; Tooher J; Ogle R; Lim S; Makris A; Hennessy A
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):839-42. PubMed ID: 19215236
[TBL] [Abstract][Full Text] [Related]
4. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
[TBL] [Abstract][Full Text] [Related]
5. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.
De Vivo A; Baviera G; Giordano D; Todarello G; Corrado F; D'anna R
Acta Obstet Gynecol Scand; 2008; 87(8):837-42. PubMed ID: 18607829
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
Jääskeläinen T; Heinonen S; Hämäläinen E; Pulkki K; Romppanen J; Laivuori H;
Pregnancy Hypertens; 2018 Oct; 14():252-259. PubMed ID: 29803331
[TBL] [Abstract][Full Text] [Related]
7. The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.
Cheng M; He P; Fu J
J Hum Hypertens; 2016 Dec; 30(12):788-793. PubMed ID: 27169826
[TBL] [Abstract][Full Text] [Related]
8. In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia.
Gangooly S; Muttukrishna S; Jauniaux E
PLoS One; 2014; 9(9):e107644. PubMed ID: 25251016
[TBL] [Abstract][Full Text] [Related]
9. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.
Gu Y; Lewis DF; Wang Y
J Clin Endocrinol Metab; 2008 Jan; 93(1):260-6. PubMed ID: 17956952
[TBL] [Abstract][Full Text] [Related]
10. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
[TBL] [Abstract][Full Text] [Related]
11. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.
Leaños-Miranda A; Campos-Galicia I; Berumen-Lechuga MG; Molina-Pérez CJ; García-Paleta Y; Isordia-Salas I; Ramírez-Valenzuela KL
J Rheumatol; 2015 Jul; 42(7):1141-9. PubMed ID: 25979720
[TBL] [Abstract][Full Text] [Related]
12. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
[TBL] [Abstract][Full Text] [Related]
13. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
[TBL] [Abstract][Full Text] [Related]
14. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.
Chedraui P; Lockwood CJ; Schatz F; Buchwalder LF; Schwager G; Guerrero C; Escobar GS; Hidalgo L
J Matern Fetal Neonatal Med; 2009 Jul; 22(7):565-70. PubMed ID: 19350449
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy.
Salahuddin S; Lee Y; Vadnais M; Sachs BP; Karumanchi SA; Lim KH
Am J Obstet Gynecol; 2007 Jul; 197(1):28.e1-6. PubMed ID: 17618745
[TBL] [Abstract][Full Text] [Related]
16. Gadd45α as an upstream signaling molecule of p38 MAPK triggers oxidative stress-induced sFlt-1 and sEng upregulation in preeclampsia.
Luo X; Yao ZW; Qi HB; Liu DD; Chen GQ; Huang S; Li QS
Cell Tissue Res; 2011 Jun; 344(3):551-65. PubMed ID: 21519896
[TBL] [Abstract][Full Text] [Related]
17. Correlations between circulating levels of adipokines and anti-angiogenic factors in women with BMI <30 and a late-onset preeclampsia.
Eleuterio NM; Palei AC; Rangel Machado JS; Tanus-Santos JE; Cavalli RC; Sandrim VC
Hypertens Pregnancy; 2014 Feb; 33(1):72-80. PubMed ID: 24380505
[TBL] [Abstract][Full Text] [Related]
18. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
19. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
